Last reviewed · How we verify
NCT03463018
Echinacea Angustifolia (AnxioCalm) in Anxiety
Phase 2 trial testing Echinacea angustifolia in Generalized Anxiety Disorder in 100 participants. Terminated before completion.
3 October 2020
Quick facts
| Lead sponsor | EuroPharma, Inc. |
|---|---|
| Phase | Phase 2 |
| Status | Terminated |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | double |
| Primary purpose | treatment |
| Enrollment | 100 |
| Start date | 6 June 2018 |
| Primary completion | 3 October 2020 |
| Estimated completion | 15 December 2021 |
| Sites | 1 location across Georgia |
Drugs / interventions tested
- Echinacea angustifolia — full drug profile →
- Placebo
Conditions studied
- Generalized Anxiety Disorder — all drugs for Generalized Anxiety Disorder →
Sponsor
EuroPharma, Inc.
Who can join
18 and older, any sex, with Generalized Anxiety Disorder. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This study evaluates whether Echinacea angustifolia (AnxioCalm) is a safe and effective treatment for mild to moderate Generalized Anxiety Disorder (GAD) symptoms. Half the participants will receive Echinacea angustifolia and half will receive placebo.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT03463018
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Generalized Anxiety Disorder
Currently open trials in the same condition.
- NCT06661460 — Internet-Delivered Cognitive Behavioral Intervention for Youths With Anxiety Disorders · NA · recruiting
- NCT06934525 — Implementing Team-Based Treatment for Pediatric Anxiety in Community Mental Health Settings · NA · recruiting
- NCT07305701 — Cohort Study on Medical Students' Mental Health · recruiting
- NCT07330648 — Prospective Clinical Trial of Crisugabalin Capsules in the Treatment of Generalized Anxiety Disorder · Phase 2 · recruiting
- NCT07121712 — Navigated cTBS for the Treatment of Generalized Anxiety Disorder · NA · recruiting
Other EuroPharma, Inc. trials
Trials by the same sponsor.
- NCT04932265 — Effect of Gamma-cyclodextrin on the Bioavailability of Ginsenosides · Phase 1 · suspended
- NCT04167449 — Effects of Korean Red Ginseng Extract on Electrical Brain Activity in Elderly Subjects · Phase 4 · completed
- NCT03780621 — Effects of an Adaptogenic Extract on Electrical Activity of the Brain in Elderly Subjects With Cognitive Impairment · Phase 1 · completed
- NCT03947554 — Ginseng HRG80 in Stress and Fatigue · Phase 1, PHASE2 · completed
- NCT03461380 — Effect of Menopause Relief EP-40 in Women With Menopausal Symptoms · Phase 2 · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT03463018 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by EuroPharma, Inc.
- Last refreshed: 24 March 2022
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03463018.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing